• Je něco špatně v tomto záznamu ?

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children

C. Claeys, V. Chandrasekaran, J. García-Sicilia, R. Prymula, J. Díez-Domingo, J. Brzostek, J. Marès-Bermúdez, F. Martinón-Torres, AJ. Pollard, R. Růžková, A. Carmona Martinez, A. Ulied, M. Miranda Valdivieso, SN. Faust, MD. Snape, D. Friel, T....

. 2019 ; 38 (2) : 203-210. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006755

BACKGROUND: It has not yet been demonstrated whether 2 doses of inactivated quadrivalent influenza vaccine (IIV4) prime a booster response in infants. We evaluated the anamnestic immune response to an IIV4 in children 17-48 months of age. METHODS: Children were randomized to 2 doses of IIV4 or control in the primary phase III study (NCT01439360). One year later, in an open-label revaccination extension study (NCT01702454), a subset of children who received IIV4 in the primary study (primed group) received 1 IIV4 dose and children who received control in the primary study (unprimed) received 2 IIV4 doses 28 days apart. The primary objective was to evaluate hemagglutination inhibition (HI) antibody titers 7 days after first IIV4 vaccination in the per-protocol cohort (N = 224 primed; N = 209 unprimed). Neutralizing and antineuraminidase antibodies were also measured. Safety was analyzed in the total vaccinated cohort (N = 241 primed; N = 229 unprimed). RESULTS: An anamnestic response was observed in primed children relative to unprimed controls, measured by age-adjusted geometric mean HI titer ratios against strains homologous (A/H1N1: 9.0; B/Victoria: 3.9) and heterologous (A/H3N2: 2.7; B/Yamagata: 6.7) to those in the primary vaccination series. The anamnestic response in primed children included increases in neutralizing antibodies (mean geometric increase: 5.0-10.6) and antineuraminidase antibodies (4.9-8.8). No serious adverse events related to vaccination were reported. CONCLUSIONS: In this study, 2-dose priming with IIV4 induced immune memory that was recalled with 1-dose IIV4 the following year to boost HI, antineuraminidase and neutralizing antibodies, even though the IIV4 strain composition partially changed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006755
003      
CZ-PrNML
005      
20200525132407.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/INF.0000000000002217 $2 doi
035    __
$a (PubMed)30325891
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Claeys, Carine $u From the GSK, Wavre, Belgium.
245    10
$a Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children / $c C. Claeys, V. Chandrasekaran, J. García-Sicilia, R. Prymula, J. Díez-Domingo, J. Brzostek, J. Marès-Bermúdez, F. Martinón-Torres, AJ. Pollard, R. Růžková, A. Carmona Martinez, A. Ulied, M. Miranda Valdivieso, SN. Faust, MD. Snape, D. Friel, T. Ollinger, J. Soni, A. Schuind, P. Li, BL. Innis, VK. Jain,
520    9_
$a BACKGROUND: It has not yet been demonstrated whether 2 doses of inactivated quadrivalent influenza vaccine (IIV4) prime a booster response in infants. We evaluated the anamnestic immune response to an IIV4 in children 17-48 months of age. METHODS: Children were randomized to 2 doses of IIV4 or control in the primary phase III study (NCT01439360). One year later, in an open-label revaccination extension study (NCT01702454), a subset of children who received IIV4 in the primary study (primed group) received 1 IIV4 dose and children who received control in the primary study (unprimed) received 2 IIV4 doses 28 days apart. The primary objective was to evaluate hemagglutination inhibition (HI) antibody titers 7 days after first IIV4 vaccination in the per-protocol cohort (N = 224 primed; N = 209 unprimed). Neutralizing and antineuraminidase antibodies were also measured. Safety was analyzed in the total vaccinated cohort (N = 241 primed; N = 229 unprimed). RESULTS: An anamnestic response was observed in primed children relative to unprimed controls, measured by age-adjusted geometric mean HI titer ratios against strains homologous (A/H1N1: 9.0; B/Victoria: 3.9) and heterologous (A/H3N2: 2.7; B/Yamagata: 6.7) to those in the primary vaccination series. The anamnestic response in primed children included increases in neutralizing antibodies (mean geometric increase: 5.0-10.6) and antineuraminidase antibodies (4.9-8.8). No serious adverse events related to vaccination were reported. CONCLUSIONS: In this study, 2-dose priming with IIV4 induced immune memory that was recalled with 1-dose IIV4 the following year to boost HI, antineuraminidase and neutralizing antibodies, even though the IIV4 strain composition partially changed.
650    _2
$a neutralizující protilátky $x krev $7 D057134
650    _2
$a protilátky virové $x krev $7 D000914
650    _2
$a předškolní dítě $7 D002675
650    _2
$a nežádoucí účinky léčiv $x epidemiologie $x patologie $7 D064420
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a testy inhibice hemaglutinace $7 D006385
650    _2
$a lidé $7 D006801
650    12
$a imunologická paměť $7 D007156
650    _2
$a kojenec $7 D007223
650    _2
$a vakcíny proti chřipce $x aplikace a dávkování $x škodlivé účinky $x imunologie $7 D007252
650    _2
$a chřipka lidská $x prevence a kontrola $7 D007251
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neutralizační testy $7 D009500
650    _2
$a inaktivované vakcíny $x aplikace a dávkování $x škodlivé účinky $x imunologie $7 D015164
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chandrasekaran, Vijayalakshmi $u GSK, King of Prussia, Pennsylvania.
700    1_
$a García-Sicilia, José $u Hospital Materno-Infantil La Paz, Madrid, Spain.
700    1_
$a Prymula, Roman $u Faculty of Medicine, University Hospital and Charles University, Hradec Králové, Czech Republic.
700    1_
$a Díez-Domingo, Javier $u Vaccine Research Department, FISABIO-Public Health, Valencia, Spain.
700    1_
$a Brzostek, Jerzy $u Infectious Diseases Outpatient Clinic, Debica, Poland.
700    1_
$a Marès-Bermúdez, Josep $u Institut Pediàtric Marès-Riera, Girona, Spain.
700    1_
$a Martinón-Torres, Federico $u Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain. Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidade de Santiago de Compostela (USC), Galicia, Spain.
700    1_
$a Pollard, Andrew J $u University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
700    1_
$a Růžková, Renata $u Pediatric Office Dr. Renáta Růžková, Prague, Czech Republic.
700    1_
$a Carmona Martinez, Alfonso $u Instituto Hispalense de Pediatría, Sevilla, Spain.
700    1_
$a Ulied, Angels $u CAP Centelles, Barcelona, Spain.
700    1_
$a Miranda Valdivieso, Mariano $u Hospital de Antequera, Málaga, Spain.
700    1_
$a Faust, Saul N $u National Institute of Health Research Wellcome Trust Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
700    1_
$a Snape, Matthew D $u University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
700    1_
$a Friel, Damien $u From the GSK, Wavre, Belgium.
700    1_
$a Ollinger, Thierry $u From the GSK, Wavre, Belgium.
700    1_
$a Soni, Jyoti $u GSK, Bangalore, India.
700    1_
$a Schuind, Anne $u GSK, Rockville, Maryland.
700    1_
$a Li, Ping $u GSK, King of Prussia, Pennsylvania.
700    1_
$a Innis, Bruce L $u GSK, King of Prussia, Pennsylvania.
700    1_
$a Jain, Varsha K $u GSK, King of Prussia, Pennsylvania.
773    0_
$w MED00003732 $t The Pediatric infectious disease journal $x 1532-0987 $g Roč. 38, č. 2 (2019), s. 203-210
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30325891 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525132407 $b ABA008
999    __
$a ok $b bmc $g 1525613 $s 1096811
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 38 $c 2 $d 203-210 $e - $i 1532-0987 $m The Pediatric infectious disease journal $n Pediatr Infect Dis J $x MED00003732
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace